# README — QSP PDAC AI Clinical Trial Simulation: Chunked Document Set

**Paper:** "QSP Metastatic Pancreatic Cancer AI Clinical Trial Simulation — From Protocol to Prediction: Code, VVUQ, and Playbook"
**Author:** Kevin Kawchak, ChemicalQDevice, San Diego, CA (August 29, 2025)
**Source DOI:** 10.5281/zenodo.17001137
**License:** CC BY 4.0
**Original source files:** main.tex (122 KB), references.bib (67 KB), README.md (original template notes)

---

## Purpose of This Document Set

This chunked document set was created to provide Claude Code Opus 4.7 (1M context window) with structured, readily-accessible content from the above paper to assist in the development of a **new physical AI oncology trial paper**. The 10 markdown chunks preserve all substantive text from the paper word-for-word, with LaTeX formatting commands stripped but all content intact. BibTeX entries are preserved verbatim in fenced code blocks.

---

## Overview of All 10 Chunk Files

### chunk_01_title_abstract.md
**Content:** Full paper title, complete author block (Kevin Kawchak, ChemicalQDevice, San Diego, CA, August 29, 2025), and the entire structured abstract with all six labeled sections: Question, Concepts, Results, Outputs, Impacts, and Outcome.

**Key information contained:**
- Central research question: Can AI generate end-to-end QSP pancreatic cancer trial protocols, Python code, VVUQ, and playbook?
- Core AI tools used: ChatGPT 5 Pro Research, Gemini 2.5 Pro, Claude Opus 4.1 Extended
- Trial scale: 10 arms, 7 archetypes, 10,000 patients, up to 250 ODEs per patient
- Key numerical results: dt = 0.05 finalized, GRID = 5, ORR error ≤ 11% for KRAS Emax sensitivity
- Financial impact: $36,304 total cost, 99.6% QSP cost reduction vs $2M industry QSP, $3.6/patient vs $59,500/patient in-person (16,528x difference)
- Top recommendation: Arm C (KRAS G12D targeted), ORR 70.8%, mOS 11.9 months (HR=0.50)

**Correlates with:** All other chunks. This is the entry point and summary of the entire paper. chunk_04 provides the detailed trial data underlying the abstract's numerical claims. chunk_07 provides the financial detail supporting the Impacts section.

---

### chunk_02_introduction_methods.md
**Content:** Section A (Introduction) and Section B (Methods) — the two main body sections written by the author.

**Key information contained:**
- QSP historical context: 2013 Natpara FDA inquiry, 60 QSP submissions in 2020
- Justification for AI-assisted QSP: FDA Project Optimus (2021), immuno-oncology QSP models by Wang et al. (2024), Flatiron Health real-world evidence
- 2025 LLM-QSP literature: Yang et al., Androulakis et al. (two papers), Goryanin et al.
- Novel claim: First end-to-end QSP oncology clinical trial with supporting documentation using conversational AI
- Methods workflow: Prior studies [18KawchakPDAC, 19KawchakSimPDAC] → Prompt 01 with ChatGPT o3-pro → iterative Python refinement → Gemini for large code revisions → Part C text conversion by ChatGPT 5
- AI tool specifications: ChatGPT 5 Research (Deep Research), Gemini 2.5 Pro (Temp=1, Top P=0.95, Thinking budget=32768, Output=65536), Claude Opus 4.1 Extended, Grok 3
- Computational environment: MacOS 14.5, Chrome 138.0.7204.169, Google Colab, VS Code

**Correlates with:** chunk_01 (Methods directly elaborates the Abstract's Concepts and Outputs sections); chunk_06 (Implementation/verification continues the code development story started in Methods); chunk_09 (Deliverables section describes the Parts A-E referenced in Methods); chunk_10a and chunk_10b (all in-text citations [01IntroCucurull] through [22IntroGoryanin] and [18KawchakPDAC], [19KawchakSimPDAC] are resolved in the reference chunks).

---

### chunk_03_playbook_trial_def_model.md
**Content:** Section 0 (QSP Simulation Playbook introduction), Section 1 (Clinical Trial Definition and Scope), and Section 2 (Mechanistic QSP Model Construction) — the full mechanistic model description including ODEs, initial conditions, and spatial structure.

**Key information contained:**
- Playbook context: Retrospective analysis of virtual Phase II PDAC trial, Parts A–D consolidated
- Trial design: 10 arms A–K (A-E first-line, G-K second-line, F as line separator), ~1,000 patients/arm, 3-year follow-up, endpoints ORR/PFS/OS/Grade≥3 AEs/drop-out
- Arm descriptions: Arm A = Gemcitabine + nab-Paclitaxel (FOLFIRINOX-like), Arms adding KRAS G12D inhibitor (C), CD47 blockade (B), PEGPH20 stromal modifier (D), dual immunotherapy (E), KRAS G12C + CD40 combos (H, I), PARP maintenance (J)
- **Core ODEs:** dV_s/dt and dV_r/dt with logistic growth and three kill terms (k_chemo, k_immune, k_target)
- **Initial conditions:** V_s(0) = (1-f_res)*V_0, V_r(0) = f_res*V_0, baseline f_res = 0.05
- Spatial structure: 3D grid GRID_SIZE (5×5×5 = 125 compartments at GRID=5), peripheral vs core drug gradients, HA_high stroma barrier
- Module breakdown: Chemotherapy → sensitive cells only; Targeted → mutation-carrying cells; Immune → both; Toxicity → composite score affecting drop-out
- Figures referenced: 2A (AI workflow), 2B (Modular QSP architecture)

**Correlates with:** chunk_04 (Section 3 continues from Section 2 with parameterization of the same model); chunk_05 (Table T1 lists the parameters for the ODEs defined here); chunk_06 (Section 4 describes implementation of these ODEs in Python; Section 5 verifies the ODEs numerically); chunk_07 (Section 6 performs sensitivity analysis on key ODE parameters f_res and Emax); chunk_08 (Section 9 calibrates the ODE model to clinical benchmarks).

---

### chunk_04_parameterization_tables.md
**Content:** Section 3 (Parameterization and Virtual Patient Population) including the cohort/arm lists, archetype definitions, the Final Trial Summary table (FTS), and the Patient Log Verification table (LOG).

**Key information contained:**
- Calibration targets: Arm A tuned to ~10.3 mo OS, ~50% ORR initially; historical MPACT data: ~8.5 mo OS, 23% ORR; final calibration: 6.9 mo OS, 14.7% ORR
- Virtual population: 10,000 patients, log-normal V0 (CV ~30%), Beta-distributed f_res, biomarker frequencies (KRAS G12D ~35-40%, KRAS G12C ~5%, gBRCA ~7%)
- **Cohort 1 (first-line):** Arms A, B, C, D, E — detailed drug combinations
- **Cohort 2 (second-line/maintenance):** Arms G, H, I, J, K — detailed drug combinations
- **Seven archetypes:** ARCH-01 Young Fit (~15%), ARCH-02 Elderly Frail (~20%), ARCH-03 Locally Advanced Fit (~10%), ARCH-04 BRCA-Mutated (~10%), ARCH-05 KRAS G12C (~5%), ARCH-06 Stroma-High (~10%), ARCH-07 Refractory (~30%)
- **Table FTS (Final Trial Summary):** Complete 10-arm results table with N, ORR%, DCR%, mPFS(HR), PFS-6, mOS(HR), OS-12, G3+/Drop% for all arms A,B,C,D,E,G,H,I,J,K at dt=0.05, GRID=5, Day 1080/1080
- **Table LOG (Patient Log):** CSV column headers; three example patients (00001, 05698, 09998) with full data across all 35 fields, shown in triplicate (B3_Final_1, B3_Final_2, B3_Final_3) plus plain-language interpretations

**Correlates with:** chunk_01 (abstract's numerical results draw directly from Table FTS); chunk_03 (parameterization builds on the model defined in Section 2); chunk_05 (Table T1 gives the specific values for parameters described in general terms in Section 3); chunk_06 (Section 4 references Table T1; Section 5 verification explains why final dt=0.05/GRID=5 were chosen for Table FTS); chunk_07 (sensitivity analysis shows how Table FTS results would shift under different f_res and Emax); chunk_08 (Section 9 validates Table FTS results against MPACT, NAPOLI-1, POLO benchmarks; Section 10 interprets Table FTS for prioritization); chunk_09 (Data Availability lists the file B1_Final_Trial_Code that produces Table FTS and B3_Final files that produce Table LOG).

---

### chunk_05_table_T1_parameters.md
**Content:** Complete Table T1 — the comprehensive parameter catalog for the QSP model, with 14 rows covering all major parameters.

**Key information contained:**
- **r_s:** ~0.0115/day (range 0.008-0.014), ~60-day doubling time, ±20% variation
- **r_r:** ~0.011/day, no major fitness cost for resistance
- **f_res:** 5% baseline (Beta distribution 0-10%), high-impact parameter
- **K:** ~4× initial tumor volume, logistic growth cap
- **k_chemo:** Calibrated to Arm A; weekly dosing spikes; HA_high reduces penetration; PEGPH20 gives 1.3× multiplier
- **k_target (KRAS inhibitor):** E_max = 0.072/day, EC50 = 1 µM; 0.5× or 1.5× E_max changes Arm C ORR by only ±4-5%
- **k_immune (base):** ~1×10^−4/day; near-zero reflecting PDAC immune evasion
- **PD-1 effect:** 3-5× k_immune multiplier (pembrolizumab, Arms E/H)
- **CD40 effect:** Additional 3-5× k_immune (mitazalimab, Arms E/H/I); stacked multiplicatively
- **CD47 effect:** Small macrophage kill term (magrolimab, Arm B)
- **Toxicity thresholds:** Drug-specific contributions; Grade≥3 AE calibration targets; drop-out rates (Arm E ~22.8% initial, Arm H ~17%, Arm A ~10%)
- **V0:** Log-normal, CV ~30%
- **RECIST:** ≥30% reduction = PR; ≥20% growth from nadir = PD

**Correlates with:** chunk_03 (Table T1 provides the specific numerical values for the equations and modules described in Section 2); chunk_04 (Table T1 is referenced in the Section 3 text and directly supports the calibration approach described there); chunk_06 (Section 4 explicitly references Table T1 for the parameter catalog; Section 5 verification uses these parameters to confirm numerical stability); chunk_07 (sensitivity analysis in Section 6 focuses on f_res and E_max — two of the most critical parameters in Table T1); chunk_08 (Section 9 oncology calibration cross-references real clinical data against Table T1 calibration targets).

---

### chunk_06_implementation_verification.md
**Content:** Section 4 (Model Implementation and Reverse-Engineering) and Section 5 (Verification and Validation of QSP Clinical Trial).

**Key information contained:**
- **Part B implementation:** LLM-generated Python code from Part A protocol; modular design (initialization, treatment, ODE integration, output); fixed-step solver; dt = 0.1–0.5 days initially
- **Part C reverse-engineering:** LLM converts Python back to plain text for cross-checking; caught one error (CD40 effect missing from Arm E)
- **Model stack workflow:** Part A → Part B (LLM code) → Part C (code-to-text) → Part D (VVUQ/this analysis); Python 3.12 + NumPy/Pandas/matplotlib; Google Colab (dual-core 13 GB CPU → TPU 173 GB RAM)
- **Parameter scale:** 50-100 adjustable parameters; ~20 biophysical, ~10 toxicity/PK, 16 Emax/EC50 pairs; binary mutation flags per patient; 2.5M tumor volume states per time-step
- **dt verification results:**
  - dt ≤ 0.05 or 0.1: ~0% ORR (stable)
  - dt = 0.25: Arm A ~5% ORR
  - dt = 0.45: Arm A ~27% ORR
  - dt = 0.50: Arm A ~31.5% ORR (plateau with Arm C ~70%)
  - Final choice: dt = 0.05 (confirmed equal to dt = 0.1)
- **GRID_SIZE verification:** GRID=2 underestimates; GRID=5 stabilizes (<1% change at 5→6→7); GRID=5 final
- **Biological validation:** Arm G (PD-1 only) = 0% ORR confirmed; Arm A = ~15% ORR, 6.9 mo OS (slightly below MPACT benchmarks but plausible)
- Figures referenced: 2A (workflow), 5A (convergence charts for dt and grid)

**Correlates with:** chunk_03 (Section 4 implements the model equations defined in Section 2; the "model stack" continues the workflow narrative from Methods); chunk_04 (the dt=0.05/GRID=5 settings confirmed here produce the Table FTS results in chunk_04); chunk_05 (Table T1 parameters are the inputs to the code validated in Section 5); chunk_07 (numerical stability results from Section 5 directly feed into the dt and GRID choices used for sensitivity analysis in Section 6); chunk_09 (Data Availability files B4_Verify_Time_Step and B5_Verify_Grid_Size contain the experimental data described in Section 5).

---

### chunk_07_sensitivity_QA_compute.md
**Content:** Section 6 (Sensitivity Analysis and Uncertainty Quantification), Section 7 (Quality Assurance and Protocol Compliance), and Section 8 (Computational Efficiency and Scalability).

**Key information contained:**
- **f_res sensitivity (Section 6):** ORR drops 6-fold (Arm A: ~31.5% → ~5.7%) as f_res goes from 5% → 30%; Arms B/D/E/H/I drop >50%; Arms C and J are more resistant to f_res changes
- **Emax sensitivity (Section 6):** Arm C ORR: 66.4% (0.5×) → 70.3% (baseline) → 71.9% (1.5×); near-plateau regime; conclusions robust to potency uncertainty
- Supplementary analyses: B6 (resistant tumor volume derivatives), B9 (EC50 MRTX)
- **QA Protocol (Section 7):** Cross-checking OS HRs vs K-M curves; PFS-6/OS-12 consistency with median values
- **ODE count (Section 7):** 250 ODEs/patient (125 compartments × 2 state variables); 2.5M total ODEs conceptually; exceeds prior QSP models by orders of magnitude
- **PDE note:** Spatial PDE approximated as reaction-diffusion ODEs on grid (not solved in continuous form)
- **Compute performance (Section 8):** 0.5-1.0 sec/patient on v6e-1 TPU; 10k patients in ~2-3 min with 64 TPU cores; Google Colab (dual-core $0.007/hr → TPU $0.374/hr); ~$4 total Colab credits
- **Cost breakdown (Section 8):** $36,304 total ($36,000 labor at $150/hr × 60 hr/wk × 4 wk + $300 AI subscriptions: OpenAI $260, Anthropic $20, Google $20, xAI $0)
- Figures referenced: 6A (f_res sensitivity), 6B (Emax heatmap), 8A (runtime vs resolution)

**Correlates with:** chunk_01 (abstract's Results section directly quotes the Emax ORR error ≤11% and mentions UQ for clone parameters — both from Section 6); chunk_03 (f_res was defined as the initial resistant fraction in the ODE model equations); chunk_05 (Table T1 lists f_res and E_max as the specific parameters analyzed in Section 6); chunk_06 (Section 5's dt/GRID verification results feed into the stable parameter space explored in Section 6); chunk_08 (Section 9 uses the calibrated parameters to validate against external data; Section 10 interprets which arms are most robust given UQ findings); chunk_09 (Data Availability files B6-B9 contain the sensitivity analysis experiments).

---

### chunk_08_calibration_findings.md
**Content:** Section 9 (Oncology-Specific Calibration and Validation) and Section 10 (Key Findings and Comparative Insights).

**Key information contained:**
- **Section 9 calibration benchmarks:**
  - Arm A vs MPACT: Model 6.9 mo OS / 14.7% ORR vs clinical 8.5 mo / 23% ORR (conservative but plausible)
  - Gemcitabine monotherapy: Model 6.3 mo OS / 0% ORR vs clinical 5.7-6.8 mo / 7-9% ORR
  - Arm G vs NAPOLI-1: Model 5.4 mo OS / 0% ORR vs clinical ~6.1 mo / 7% ORR
  - Arm B (magrolimab): Model 17.3% ORR, 7.6 mo OS vs Arm A 14.7% / 6.9 mo (modest improvement)
  - Arm A Grade≥3 AEs: 84% (model) vs ~85% (FOLFIRINOX clinical benchmark)
  - Drop-outs: Arm E 14.2%, Arm H 18.3%, Arm I 5.8%, Arm A 5.6%
- **Resistance/biology assumptions:** Purely intrinsic f_res (no acquired resistance); represents upper-bound OS estimates
- **Section 10 key findings:**
  - Top performers: Arms C, H, I, J (KRAS-targeted and BRCA-maintenance)
  - Arm C: 70.8% ORR, 11.9 mo mOS (HR=0.50) — best first-line
  - Arm H: 67.7% ORR, 12.8 mo mOS (HR=0.25) — highest OS gain vs control
  - Arm I: 67.2% ORR, 12.8 mo mOS (HR=0.23) — similar to H, much lower toxicity
  - Arm J: 68.5% ORR, 12.3 mo mOS (HR=0.34) — BRCA-maintenance validated
  - Arm E: Risk >> Benefit (toxicity overwhelms efficacy); should not proceed
  - Arm D (PEGPH20): Confirms HALO-301 failure — ORR up but no OS benefit
  - Chemo role: Still essential in broad populations; substitutable in KRAS G12C subset
  - Immunotherapy dilemma: Monotherapy ineffective; combination logic key
  - Immunogenic cell death insight: Targeted + immuno (Arm I) generalizable beyond KRAS G12C
- Figures referenced: 10A (HRs and subgroup panels), 10B (waterfall plots), 10C (radar/forest plots), 10D (stratified waterfall, violin, tumor reduction vs OS Pearson r ≈ -0.93)

**Correlates with:** chunk_01 (abstract's Outcome section summarizes Section 10 recommendations); chunk_04 (Table FTS values are the source data for all Section 9 and Section 10 comparisons); chunk_05 (calibration targets for Table T1 parameters are validated in Section 9); chunk_07 (Section 6 uncertainty findings (especially f_res) contextualize the Section 10 optimism caveats); chunk_09 (Sections 11-12 extend the limitations and future work implied by Section 9-10 findings).

---

### chunk_09_limitations_future_deliverables.md
**Content:** Section 11 (Limitations and QSP Trial Conclusions), Section 12 (Future Work and Model Extensions), Section 13 (Deliverables and Impact), Section 14 (Financial Assessments), Data Availability, Acknowledgments, Ethical Disclosures, Rights and Permissions, and About This Study.

**Key information contained:**
- **Section 11 limitations (6 major points):**
  1. No acquired resistance (optimistic OS tails)
  2. Data gaps for experimental agents (CD47, CD40 in PDAC)
  3. Numerical stability: dt=0.5 inflated ORR; dt=0.05 corrected Arm A from 50% to 15%
  4. Biology vs artifacts (mPFS and Grade 3 AEs remained suboptimal)
  5. Generality: comparative not absolute predictions
  6. AI integration limits: effective for first drafts, limited parameter modifications at scale
- **Section 12 future work (6 directions):**
  1. Acquired resistance stochastic module
  2. Explicit T cell/macrophage ODE modeling
  3. Adaptive/biomarker-driven umbrella trial design
  4. Cost-effectiveness and QALY analysis
  5. Other indications (earlier-stage PDAC, other cancers)
  6. PK sub-models, toxicity type distinctions, collaboration with experimentalists
- **Section 13 deliverables:** Parts A-E + Figures described with use-case context; plain language vs code deliverables; data sharing rationale
- **Section 14 financial figures:** Figure 14A (industry QSP $2M vs real trials); Figure 14B (current study ROI, ~300× cheaper than Phase II, ~1000× cheaper than Phase III, 24-40× faster)
- **Data Availability:** Full hierarchical file listing (A1 through F1_Trial_Images, Zenodo source [20KawchakQSPPDAC])
- CC BY 4.0 license; no competing interests; full citation

**Correlates with:** chunk_01 (Impacts in abstract references the financial figures described in Section 14); chunk_02 (Methods describes the AI tools whose limits are acknowledged in Section 11); chunk_06 (the dt artifact corrected in Section 5 is the "numerical stability" limitation acknowledged in Section 11); chunk_07 (Section 8 compute costs feed into Section 14 financial assessments); chunk_08 (Section 10 recommendations are the actionable outputs of the deliverables in Section 13); chunk_10a and chunk_10b (citation [20KawchakQSPPDAC] in Data Availability is resolved in chunk_10a).

---

### chunk_10a_references_part1.md
**Content:** BibTeX references — Part A: AI tools and platforms, author's prior works (Kawchak references 01–20 and GitHub), and general AI/LLM literature.

**Key information contained:**
- All OpenAI model references (GPT-4o, o1, o3, o3-pro, o3-mini, ChatGPT 5/GPT-5)
- Anthropic references (Claude 3.5 Sonnet, 3.7 Sonnet, Claude 4, Sonnet 4, Opus 4, Opus 4.1)
- Google references (Gemini, Google AI Studio, Gemini 2.5 Pro, Flash Thinking)
- Infrastructure: Google Colab, VS Code, Google Docs, Google Scholar, DeepSeek-R1
- Agent frameworks: LangChain, AutoGen, CrewAI
- Author's 20-paper Zenodo/ChemRxiv/bioRxiv publication series (01Kawchak through 20KawchakQSPPDAC, GitHub repositories)
- General LLM/inference papers: Ferraris et al. 2025, Xu et al. 2025, An et al. 2024, Li et al. 2024 inference survey, OpenAI system cards

**Correlates with:** chunk_02 (introduction cites [18KawchakPDAC], [19KawchakSimPDAC]; methods cites [ChatGPT5DR], [Google_AI_Studio], [Opus41], [ChatGPTo3], [Grok3], [GoogleColab], [Visual_Studio_Code]); chunk_01 (abstract references these AI tools); chunk_09 ([20KawchakQSPPDAC] is cited in Data Availability and About This Study).

---

### chunk_10b_references_part2.md
**Content:** BibTeX references — Part B: Cancer and oncology LLM literature, QSP and clinical pharmacology (Introduction references), and clinical trial references.

**Key information contained:**
- **Cancer LLM literature:** CancerLLM, pancreatic cancer early detection via LLM (Zack et al.), PDAC radiology LLM, precision oncology LLM papers (Lammert, Das, Benary, etc.), JAMA papers (Naik, Longwell), breast cancer LLM review (Sorin), prostate cancer LLMs, radiation oncology LLMs
- **QSP/Intro references ([01Intro] through [22Intro]):**
  - QSP industry perspectives: Cucurull-Sanchez 2024, Peterson/Riggs 2015 (FDA watershed), Galluppi 2021, Madabushi 2019
  - FDA initiatives: Project Optimus (Venkatakrishnan), MIDD Program
  - Immuno-oncology QSP: Wang et al. 2024 (npj Digital Medicine), Gong et al. 2021 (spQSP-IO)
  - PDAC biology: Hartupee et al. 2024 (tumor microenvironment)
  - Virtual populations: Cheng 2022, Iwata 2025, Rieger 2018
  - LLM-QSP integration: Androulakis et al. 2025 (two papers), Yang et al. 2025, Goryanin et al. 2025
  - PDAC treatment consensus: Wang et al. 2024 (J Hematol Oncol)
- **Clinical trial references:**
  - [01PaperFolfironox]: FOLFIRINOX Phase 2 (Park et al., JAMA Oncol 2020)
  - [02PaperGem]: Gemcitabine + nab-paclitaxel Phase 2 (Shroff et al., JAMA Oncol 2019)
  - [03PapernalIRI5FU]: nal-IRI + 5-FU NIFTY trial (Yoo et al., JCO 2021) — Arm G control arm basis

**Correlates with:** chunk_02 (Introduction in-text citations [01IntroCucurull] through [22IntroGoryanin] are resolved here; clinical arm references [01PaperFolfironox], [02PaperGem], [03PapernalIRI5FU] support the trial arm definitions in chunk_03); chunk_08 (NAPOLI-1 which Arm G is compared against in Section 9 is referenced via [03PapernalIRI5FU]; MPACT and POLO trial comparisons in Section 9 use the same benchmark framework); chunk_04 (Arm G control arm uses nal-IRI + 5-FU/LV [03PapernalIRI5FU]; Arm A uses gemcitabine + nab-paclitaxel [02PaperGem]).

---

## Cross-File Correlation Map

The following table summarizes the primary cross-references between chunks that will be most useful for constructing a new physical AI oncology trial paper:

| When working on… | Essential companion chunks |
|------------------|---------------------------|
| Paper title/framing/abstract | chunk_01 ↔ chunk_04 (FTS data), chunk_09 (financials) |
| Introduction/background | chunk_02 ↔ chunk_10b (intro references [01Intro]-[22Intro]) |
| Methods/AI tools | chunk_02 ↔ chunk_10a (AI platform references) |
| Trial design/arm structure | chunk_03 ↔ chunk_04 (archetypes, arm definitions) |
| Mathematical model (ODEs) | chunk_03 ↔ chunk_05 (Table T1 parameters) ↔ chunk_06 (implementation) |
| Numerical stability/VVUQ | chunk_06 (Section 5) ↔ chunk_07 (Section 6) ↔ chunk_09 (limitations) |
| Results/trial outcomes | chunk_04 (Table FTS) ↔ chunk_08 (Section 9-10 interpretation) |
| Cost/financial analysis | chunk_07 (Section 8) ↔ chunk_09 (Section 14) ↔ chunk_01 (abstract Impacts) |
| Limitations/future work | chunk_09 ↔ chunk_08 (Section 10 informs future work in Section 12) |
| Reference lookup (AI tools) | chunk_10a |
| Reference lookup (clinical/QSP) | chunk_10b |

---

## Guidance for Claude Code Opus 4.7

When using this document set to assist in writing a new physical AI oncology trial paper, note the following:

1. **Model architecture (chunks 03, 05, 06):** The ODE framework (dV_s/dt, dV_r/dt), parameter choices (Table T1), and Python implementation (Section 4) collectively describe a complete template for a new QSP simulation. Adapt the ODEs and parameters for the new indication while maintaining the modular architecture.

2. **Trial design template (chunks 03, 04):** The 10-arm, 7-archetype, two-cohort structure with Cohort 1 (first-line) and Cohort 2 (second-line/maintenance) is directly replicable. The patient log format (35 CSV columns in Table LOG) provides an exact template for new simulation output schemas.

3. **VVUQ workflow (chunks 06, 07):** The dt/grid convergence testing (B4, B5 file series) and sensitivity analyses (B6-B9 file series) constitute a complete VVUQ protocol that should be reproduced or adapted for any new simulation.

4. **Financial framing (chunks 07, 09):** The $36,304 cost structure and comparisons to industry QSP ($2M), Phase II ($10.2M), and per-patient costs ($3.6 vs $59,500) provide a validated economic framework transferable to other cancer types.

5. **AI tool roles (chunk 02):** The division of labor — ChatGPT for text production, Gemini for large-code generation at scale (>1,300 lines), Opus for visualization conversion — represents an empirically-tested multi-model workflow.

6. **Citation infrastructure (chunks 10a, 10b):** All 22 Introduction references ([01IntroCucurull] through [22IntroGoryanin]) plus 20 Kawchak author works and 3 clinical trial baselines are available as ready-to-cite BibTeX entries for a new paper.

7. **Figure naming convention:** Figures are numbered by section (2A, 2B, 5A, 6A, 6B, 8A, 10A-D, 14A-B). This convention can be adapted for a new paper while maintaining section-figure traceability.
